MedPath

the influence of traditional Chinese medicine on the frequency and median recurrence time of dupilumab for patients with moderate and severe atopic dermatitis

Early Phase 1
Recruiting
Conditions
atopic dermatitis
Registration Number
ITMCTR2024000055
Lead Sponsor
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) meet the diagnostic criteria of Hanifin and Rajka.
(2) No sex limit, age 6-65 years old
(3) patients with moderate and severe atopic dermatitis, eczema area and severity index (EASI) = 7 or IGA score = 3
(4) the patient himself or his agent agrees to be treated with dupilumab.
(5) patients whose blood system, liver, kidney, heart and other systems are basically normal.
(6) patients with good compliance, who can be injected with dupilumab at a specified time and fill in the data such as the scale regularly.

Exclusion Criteria

(1) patients with other skin diseases such as scabies, psoriasis, seborrheic dermatitis that affect the judgment of skin lesions.
(2) patients suffering from mental diseases, malignant tumors, diabetes and heart disease, pregnant and lactating women.

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
median recurrence time;relapse rate;
Secondary Outcome Measures
NameTimeMethod
i-VAS(insomnia visual analog scale);IGA(inventor global assessment);p-VAS(pruritus visual analog scale);DLQI(dermatology life quality index);EASI(eczema area and severity index);POEM(patient oriented eczema measure);SCORAD(scoring for Atopic Dermatitis );
© Copyright 2025. All Rights Reserved by MedPath